Clinical momentum Tune Therapeutics is advancing a leading epigenetic therapy platform with TEMPO and has announced positive phase 1b/2a proof of concept data for TUNE-401 in Hepatitis B, signaling near-term clinical readouts that could attract partnerships or out-licensing discussions with biopharma seeking novel epigenetic approaches.

Strategic leadership With new CEO John McHutchison joining in 2025, the company is strengthening its clinical development execution and strategic direction, an appealing signal for potential collaborators or investors seeking a well-guided translational program and accelerated timelines.

Financing stance Having completed a $175M Series B and total funding around $215M, Tune Therapeutics combines substantial capital with a clear growth trajectory, enabling conversations around co-development, regional expansion, and access to resources for larger-scale trials and manufacturing.

Global expansion Recent moves include planning clinical trials in Hong Kong and presenting at major conferences across Europe and the US, presenting opportunities to discuss regional regulatory strategies, manufacturing partnerships, and market-entry collaborations in Asia-Pacific and Europe.

Industry positioning As an epi-therapeutics innovator targeting cancer pathways, genetic diseases, and aging with a non-permanent gene expression tuning approach, Tune positions itself to engage with gene therapy, pharmaceutical, and biotech partners seeking complementary modalities to expand their epigenetic portfolios.